Part B's Foreign Price Bench-marking Will Only Hurt Bad Negotiators, HHS's Azar Argues
President Trump touts CMS proposal that would peg Part B prices to an international index in the hopes of lowering US costs; industry calls it foreign price controls and warns it will hinder access.
You may also be interested in...
Scrip Asks...What Does 2019 Hold For Biopharma? Part 3: Pricing, Reimbursement And Market Access
How much therapies should cost and how they should be reimbursed are questions that are expected to dominate in 2019, according to industry experts and participants interviewed by Scrip on their expectations for the coming year. This is the focus for the final installment of our three-part Scrip Asks series.
CVS CEO Larry Merlo On What Comes Next After Aetna Merger
One day after CVS' $70bn acquisition of Aetna closed, CEO Larry Merlo spoke at the Forbes Healthcare Summit about why the vertical integration makes sense and how it will contribute to lower healthcare spending.
No, It's Not Just Out-Of-Pocket Costs That Are A Problem, John Arnold Tells Pharma
The billionaire philanthropist and industry agitator took the stage at the Forbes Healthcare Summit to discuss why his foundation is focused on fixing drug pricing and supporting organizations like ICER and Patients for Affordable Drugs.